Abstract| Volume 23, ISSUE 10, SUPPLEMENT , S85, October 2017

Efficacy of Tolvaptan for the Initial Hospitalized Patients With Acute Decompensated Heart Failure (ADHF)

      Aim: The purpose of this study is to evaluate the efficacy of TLV for the initially hospitalized patients with ADHF. Methods: From 2011 to 2013, consecutive 124 patients initially hospitalized with a diagnosis of ADHF (clinical scenario 2/5) at Nagoya Heart Center. They were treated with or without TLV (TLV (−); n = 81, TLV (+); n = 43). We retrospectively analyzed the clinical outcome of these patients. Results: The results are shown in the Table 1 and Fig. 1. 39.5% of cases were re-hospitalized. In the re-hospitalized cases, the incidence of WRF was significantly higher. Conclusion: the treatment with tolvaptan could shortened the duration of bed-rest and prevent WRF and re-hospitalization. The results of this study suggest tolvaptan initiated for acute treatment of patients initially hospitalized with ADHF had effect outcome in daily clinical practice.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect